Pricing Log in Create free account
Saturday 31 October 2026 Export PFE’s income statement to Excel — free account

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

30.50 0.55 +1.84%
Market cap
$170.7B
P/E
40.1×
Fwd P/E
18.6×
Dividend yield
7.05%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Pfizer Inc. 8-K filed Dec 14, 2023

Period ended Dec 14, 2023 · Filed · accepted 7:51 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release